Mechanism of action of octreotide in acromegalic tumours in vivo using dynamic contrast-enhanced magnetic resonance imaging

Pituitary

Volumn 10, Issue 3, 2007, Pages 233-236

  Sathyapalan, Thozhukat ^a   Lowry, Martin ^a   Turnbull, Lindsay W ^a   Rowland Hill, Chris ^b   Atkin, Stephen L ^a  

^a UNIVERSITY OF HULL   (United Kingdom)

^b HULL ROYAL INFIRMARY   (United Kingdom)

Author keywords

Acromegaly; Angiogenesis; DCE MRI; Dopamine agonist; Octreotide

Indexed keywords

OCTREOTIDE;

ACROMEGALY; ADULT; AGED; ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER INHIBITION; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; DRUG DOSE INCREASE; DRUG RESPONSE; HUMAN; HYPOPHYSIS ADENOMA; IN VITRO STUDY; IN VIVO STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; TREATMENT DURATION;

ACROMEGALY; ADENOMA; ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS, HORMONAL; CONTRAST MEDIA; DRUG RESISTANCE, NEOPLASM; FEMALE; GADOLINIUM DTPA; GROWTH HORMONE-SECRETING PITUITARY ADENOMA; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; OCTREOTIDE; REGIONAL BLOOD FLOW; SOMATOSTATIN;

EID: 35848962951     PISSN: 1386341X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11102-007-0044-8     Document Type: Article

References (21)

1. Bevan JS (2005) Clinical review: The antitumoral effects of somatostatin analog therapy in acromegaly. J Clin Endocrinol Metab 90:1856-1863
2. Bevan JS, Atkin SL, Atkinson AB et al. (2002) Primary medical therapy for acromegaly: An open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size. J Clin Endocrinol Metab 87:4554-4563
3. Ferjoux G, Bousquet C, Cordelier P et al. (2000) Signal transduction of somatostatin receptors negatively controlling cell proliferation. J Physiol Paris 94:205-210
4. Lamberts SW, Reubi JC, Krenning EP (1994) The role of somatostatin analogs in the control of tumor growth. Semin Oncol 21:61-64
5. Buscail L, Esteve JP, Saint-Laurent N et al. (1995) Inhibition of cell proliferation by the somatostatin analogue RC-160 is mediated by somatostatin receptor subtypes SSTR2 and SSTR5 through different mechanisms. Proc Natl Acad Sci USA 92:1580-1584
6. Losa M, Ciccarelli E, Mortini P et al. (2001) Effects of octreotide treatment on the proliferation and apoptotic index of GH-secreting pituitary adenomas. J Clin Endocrinol Metab 86:5194-5200
7. Garcia de la Torre N, Wass JA, Turner HE (2002) Antiangiogenic effects of somatostatin analogues. Clin Endocrinol (Oxf) 57:425-441
8. Dasgupta P (2004) Somatostatin analogues: Multiple roles in cellular proliferation, neoplasia, and angiogenesis. Pharmacol Ther 102:61-85
9. Adams RL, Adams IP, Lindow SW, Zhong W, Atkin SL (2005) Somatostatin receptors 2 and 5 are preferentially expressed in proliferating endothelium. Br J Cancer 92:1493-1498
10. Mross K, Fuxius S, Drevs J (2002) Serial measurements of pharmacokinetics, DCE-MRI, blood flow, PET and biomarkers in serum/ plasma - what is a useful tool in clinical studies of anti-angiogenic drugs? Int J Clin Pharmacol Ther 40:573-574
11. Tofts PS, Kermode AG (1991) Measurement of the blood-brain barrier permeability and leakage space using dynamic MR imaging. 1 Fundamental concepts. Magn Reson Med 17:357-367
12. Zirrgiebel U, Drevs J (2003) Surrogate marker in clinical studies with anti-angiogenic drugs. Int J Clin Pharmacol Ther 41:600-602
13. Tofts PS (1996) Optimal detection of blood-brain barrier defects with Gd-DTPA MRI-the influences of delayed imaging and optimised repetition time. Magn Reson Imaging 14:373-380
14. Brix G, Semmler W, Port R, Schad LR, Layer G, Lorenz WJ (1991) Pharmacokinetic parameters in CNS Gd-DTPA enhanced MR imaging. J Comput Assist Tomogr 15:621-628
15. Larsson HB, Tofts PS (1992) Measurement of blood-brain barrier permeability using dynamic Gd-DTPA scanning - a comparison of methods. Magn Reson Med 24:174-176
16. Landolt AM, Haller D, Lomax N et al (2000) Octreotide may act as a radioprotective agent in acromegaly. J Clin Endocrinol Metab 85:1287-1289
17. Pollock BE, Nippoldt TB, Stafford SL, Foote RL, Abboud CF (2002) Results of stereotactic radiosurgery in patients with hormone-producing pituitary adenomas: Factors associated with endocrine normalization. J Neurosurg 97:525-530
18. Cozzi R, Barausse M, Asnaghi D, Dallabonzana D, Lodrini S, Attanasio R (2001) Failure of radiotherapy in acromegaly. Eur J Endocrinol 145:717-726
19. Mao XW (2006) A quantitative study of the effects of ionizing radiation on endothelial cells and capillary-like network formation. Technol Cancer Res Treat 5:127-134
20. Castinetti F, Taieb D, Kuhn JM et al (2005) Outcome of gamma knife radiosurgery in 82 patients with acromegaly: Correlation with initial hypersecretion. J Clin Endocrinol Metab 90:4483-4488
21. Ferjoux G, Bousquet C, Cordelier P et al. (2000) Signal transduction of somatostatin receptors negatively controlling cell proliferation. J Physiol Paris 94:205-210